Literature DB >> 14748776

The risk of cancer from azathioprine as a treatment for multiple sclerosis.

L Taylor, R A C Hughes, K McPherson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14748776     DOI： 10.1046/j.1351-5101.2003.00721.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  12 in total

Review 1.  Azathioprine prescribing in neurology.

Authors:  P Goldsmith; G Lennox; N Bhalla
Journal:  J Neurol       Date:  2008-05-16       Impact factor: 4.849

Review 2.  Complications of Cardiac Transplantation.

Authors:  Luciano Potena; Andreas Zuckermann; Francesco Barberini; Arezu Aliabadi-Zuckermann
Journal:  Curr Cardiol Rep       Date:  2018-07-10       Impact factor: 2.931

3.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

4.  Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: their role in malignancy development and response to therapy.

Authors:  Zorica Milosevic; Nikola Tanic; Jasna Bankovic; Tijana Stankovic; Marko Buta; Dragana Lavrnic; Zorka Milovanovic; Gordana Pupic; Sonja Stojkovic; Vedrana Milinkovic; Yasuhiro Ito; Radan Dzodic
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

5.  The development of primary central nervous system B-cell lymphoma in multiple sclerosis.

Authors:  Mark K Lyons; Orland K Boucher; Barry D Birch; Naresh P Patel
Journal:  Neurohospitalist       Date:  2011-07

Review 6.  Azathioprine for multiple sclerosis.

Authors:  I Casetta; G Iuliano; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 7.  Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Authors:  Alex Gutierrez-Dalmau; Josep M Campistol
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study.

Authors:  Loredana La Mantia; Maria Donata Benedetti; Milena Sant; Alessia d'Arma; Sonia Di Tella; Roberto Lillini; Laura Mendozzi; Antonio Marangi; Marco Turatti; Domenico Caputo; Marco Rovaris
Journal:  Neurol Sci       Date:  2021-03-31       Impact factor: 3.307

9.  Candidate cancer-targeting agents identified by expression-profiling arrays.

Authors:  Vittavat Termglinchan; Wachiraporn Wanichnopparat; Kulachanya Suwanwongse; Chunhakarn Teeyapant; Kanticha Chatpermporn; Kanchana Leerunyakul; Khwanruthai Chuadpia; Onpailin Sirimaneethum; Parinya Wijitworawong; Wattanakitch Mutirangura; Chatchawit Aporntewan; Chanida Vinayanuwattikun; Apiwat Mutirangura
Journal:  Onco Targets Ther       Date:  2013-04-23       Impact factor: 4.147

Review 10.  Azathioprine. Safety profile in multiple sclerosis patients.

Authors:  L La Mantia; N Mascoli; C Milanese
Journal:  Neurol Sci       Date:  2007-12       Impact factor: 3.830
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.